🇺🇸 FDA

Intelligence · Patent portfolio

Regeneron UK Patents

Full USPTO pharma patent portfolio for Regeneron UK — grant dates, expiration, and drug cross-links.

Patents
837
Expiring ≤24m
26

Quick answer

Regeneron UK has 837 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 26 expire within 24 months — use filters for patent-cliff planning.

Page 12 of 18

  1. US 10106616

    Antagonist antibodies to human prolactin receptor (PRLR)

    Expires Mon Oct 18 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 10106610

    Antibodies comprising chimeric constant domains

    Expires Mon Oct 18 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 10081670

    Human antibodies to Ebola virus glycoprotein

    Expires Mon Sep 20 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 10076571

    Methods for reducing lipoprotein(a) levels by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)

    Expires Mon Sep 13 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 10077311

    Human antibodies to GFR alpha3 and methods of reducing pain associated with GFR alpha3-related diseases

    Expires Mon Sep 13 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 10072076

    Human antibodies to NAv1.7

    Expires Mon Sep 06 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 10072086

    Stabilized formulations containing anti-interleukin-6 receptor (IL-6R) antibodies

    Expires Mon Sep 06 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 10070632

    Rodents having a humanized TMPRSS gene

    Expires Mon Sep 06 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 10070631

    Rodents having a humanized TMPRSS gene

    Expires Mon Sep 06 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 10066017

    Methods for treating chronic sinusitis with nasal polyps by administering an IL-4R antagonist

    Expires Mon Aug 30 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 10059771

    Methods for treating nasal polyposis by administering an IL-4R antagonist

    Expires Mon Aug 23 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 10047152

    Human antibodies to fel D1 and methods of use thereof

    Expires Mon Aug 09 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 10047160

    Anti-EGFRvIII antibodies and uses thereof

    Expires Mon Aug 09 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 10047153

    Human antibodies to Fel d1 and methods of use thereof

    Expires Mon Aug 09 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 10023916

    Markers of tumor cell response to anti-cancer therapy

    Expires Mon Jul 12 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 10023641

    Anti-TIE2 antibodies and uses thereof

    Expires Mon Jul 12 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 10023642

    Anti-PDGFR-beta antibodies and uses thereof

    Expires Mon Jul 12 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 10023644

    Antigen-binding proteins that activate the leptin receptor

    Expires Mon Jul 12 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 10023654

    Anti-PCSK9 antibodies

    Expires Mon Jul 12 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 10015953

    Non-human animals having a humanized cluster of differentiation 47 gene

    Expires Mon Jul 05 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 10011647

    IL-33 antagonists and uses thereof

    Expires Mon Jun 28 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 10005834

    Biomarkers related to interleukin-33 (IL-33)-mediated diseases and uses thereof

    Expires Mon Jun 21 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 10000564

    Methods of treating an inflammatory condition or sensitivity to an allergen with anti-IL-33 antibodies

    Expires Mon Jun 14 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 9986724

    Genetically modified non-human animals and methods of use thereof

    Expires Mon May 31 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 9987500

    Human antibodies to PD-1

    Expires Mon May 31 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 9982013

    Readily isolated bispecific antibodies with native immunoglobulin format

    Expires Mon May 24 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 9968674

    Methods and compositions comprising a combination of a VEGF Trap and an anti-CTLA-4 antibody

    Expires Mon May 10 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 9968653

    Angiopoietin-based interventions for treating cerebral malaria

    Expires Mon May 10 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 9951132

    Anti-prokineticin receptor (PROKR) antibodies and uses thereof

    Expires Mon Apr 19 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 9950076

    Maytansinoid derivatives, conjugates thereof, and methods of use

    Expires Mon Apr 19 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 9951127

    Anti-ANGPTL3 antibodies and uses thereof

    Expires Mon Apr 19 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 9951141

    Antibody-drug conjugates, their preparation and their therapeutic use

    Expires Mon Apr 19 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 9943594

    Methods for the treatment of rheumatoid arthritis

    Expires Mon Apr 12 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 9938345

    Human antibodies to PD-L1

    Expires Mon Apr 05 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 9938339

    Method for treating an eye disease or disorder by administering an antibody that binds angiopoietin-2

    Expires Mon Apr 05 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 9932398

    Restricted immunoglobulin heavy chain mice

    Expires Mon Mar 29 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 9926369

    Methods for treating hepatocellular cancer by administering an anti-Ang-2 antibody

    Expires Mon Mar 22 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 9913461

    Genetically modified mouse whose genome comprises a humanized CD274 gene

    Expires Mon Mar 08 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 9914763

    VEGF antagonist formulations suitable for intravitreal administration

    Expires Mon Mar 08 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 9901082

    Genetically modified non-human animals and methods of use thereof

    Expires Mon Feb 22 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 9901083

    Non-human animals having a humanized signal-regulatory protein gene

    Expires Mon Feb 22 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 9890212

    Antibodies to human GDF8

    Expires Mon Feb 08 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 9884916

    High affinity antibodies to human IL-6 receptor

    Expires Mon Feb 01 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 9840557

    Anti-IL-25 antibodies and uses thereof

    Expires Mon Dec 07 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 9840549

    Fusion polypeptides capable of activating receptors

    Expires Mon Dec 07 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 9827310

    Anti-ErbB3 antibodies and uses thereof

    Expires Mon Nov 23 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 9795121

    Humanized C3 animals

    Expires Mon Oct 19 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 9789184

    Anti-EGFR antibodies and uses thereof

    Expires Mon Oct 12 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does Regeneron UK have?

837 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do Regeneron UK patents expire?

26 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Where does this data come from?

USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.

Data attribution: Data sources · Patent directory

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.